Mesoblast are not paying for the trial other than supplying remestemcel-L.
http://investorsmedia.mesoblast.com/static-files/e63bf0d5-7dd5-46c0-8381-c2e24bacb130
- Forums
- ASX - By Stock
- MSB
- Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-303
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B |
Open | High | Low | Value | Volume |
$1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 39613 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | 1.565 |
3 | 15000 | 1.560 |
1 | 507 | 1.550 |
2 | 8950 | 1.545 |
5 | 81611 | 1.540 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 39613 | 3 |
1.575 | 6173 | 1 |
1.580 | 119061 | 10 |
1.585 | 5500 | 1 |
1.590 | 91149 | 4 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online